An observational study in Anaphylaxis Caused by Hymenoptera Venom (Disorder), sponsored by University Hospital, Angers. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by University Hospital, Angers · Observational
Allergy to Hymenoptera venom is one of the main causes of anaphylaxis in adults, and is less common in the paediatric population. It can be severe or even fatal.
Despite the use of an emergency kit, including an adrenaline auto-injector (AAI), at present only hymenoptera venom immunotherapy (VIT) is effective in preventing subsequent severe systemic reactions.
Recurrence during the 5 years following cessation of VIT is about 10-15 percent. Studies evaluating longer-term efficacy are scarce.
At the University Hospital of Angers, hundreds of patients are treated each year, and its allergology unit has been providing VIT for over 15 years.
The purpose of this stufy is to evaluate VIT efficacy among patients who were treated with VIT and ceased VIT from 2005 to 2019, at the university hospital of Angers.
Allergy to Hymenoptera venom is one of the main causes of anaphylaxis in adults, and is less common in the paediatric population. It can be severe or even fatal.
Despite the use of an emergency kit, including an adrenaline auto-injector (AAI), at present only hymenoptera venom immunotherapy (VIT) is effective in preventing subsequent severe systemic reactions.
Recurrence during the 5 years following cessation of VIT is about 10-15 percent. Studies evaluating longer-term efficacy are scarce.
At the University Hospital of Angers, hundreds of patients are treated each year, and its allergology unit has been providing VIT for over 15 years.
The purpose of this stufy is to evaluate VIT efficacy among patients who were treated with VIT and ceased VIT from 2005 to 2019, at the university hospital of Angers.
This is a monocentric and ambispective study. In the absence of opposition from the patient (within one month after the information letter was sent), the search for data of interest is carried out by consulting the participant's medical record. An investigator (doctor or intern) interviews the participant, or the legal guardian for minors, and performs a telephone survey.
Data are collected from the participants medical records. Information gathered are as follows : age, sexe, the date and symptoms following hyménoptera stings, the evolution of allergy skin testing, total and venom specific immunoglobuin E (IgE), venom specifc immunoglobulin G4 (IgG4), basophil activation tests (BAT) to hymenoptera venom, exposure to hymenoptera stings.
The telephone survey assesses potential new comorbidities and new treatments, exposure to hymeoptera stings, hymenoptera stings after VIT cessation, if known : the hymenoptera specy, the participants reaction to the sting, and the drug that has been used to treat the symptoms.
100 studies on the registry are indexed under Anaphylaxis; 20 are open to participants now.
This study's enrollment of 290 is above the median of 137 across 48 observational studies indexed under Anaphylaxis.
Browse Anaphylaxis studies →University Hospital, Angers is the lead sponsor of 478 studies on the registry; 120 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Allergy to hymenoptera venom, Treated with VIT at the university hospital of Angers, Ceased VIT between 2005 and 2019
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants that cesed VIT between 2005 and 2019, and did not withdraw his consent to participate to the study.
Other: Telephone survey
All participants are interviewed by telephone, and are asked to answer a survey.
Reccurence of a systemic reaction
The recurrence of a systemic reaction after a hymenoptera sting reported by the patient during the telephone survey.
Time frame: up to 17 years since the patient ceased hymenoptera venom immunotherapy.
To describe the evolution of the results of the allergy work-up during hymenoptera venom immunotherapy
Results of skin-testing and blood work
Time frame: up to 17 years since the patient ceased hymenoptera venom immunotherapy to the last appointement in the allergy unit.
Predicting the recurrence of systemic symptoms
To identify any predictor of the recurrence of systemic symptoms after discontinuation of hymenoptera venom immunotherapy, among the above listed parameters.
Time frame: up to 17 years since the patient ceased hymenoptera venom immunotherapy until the phone survey
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Mar 2024, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.